Skip to content
DataLookout
Menu

NCT06663839

A Study of NILK-2301 in Patients with Locally Advanced or Metastatic Low Tumor Volume (LTV) Colorectal Cancer

StatusUnknown
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Dose Limiting Toxicity (DLT)
Timeframe: Up to 12 months
Non-Tolerated Dose (NTD)
Timeframe: Up to 12 months
Maximum Tolerated Dose (MTD)
Timeframe: Up to 12 months
Adverse Events (AEs)
Timeframe: Up to 12 months

Secondary (4)

Progression Free Survival (PFS)
Overall Survival (OS)
Pharmacokinetics - Cmax
Presence of anti-drug antibodies (ADA)

Arms and interventions

NILK-2301 Single AgentExperimental

NILK-2301 will be evaluated in patients with locally advanced or metastatic low tumor volume colorectal cancer

Drugs: Biological NILK-2301

Sites

2 sites in 1 country